/kloc-people aged 0/8 and above who have been vaccinated with 2 doses of inactivated COVID-19 vaccine for 6 months can go to the nearest inoculation point for intensive immunization.

_ Safety and effectiveness of vaccine booster needle

The study on the safety of booster needle of inactivated biological COVID-19 vaccine in China showed that there was no significant difference in the total adverse reaction rate between the two doses and the three doses after the third dose was given to people aged 65,438+08-59 and over 60 years old in phase I/II clinical trials.

According to the data of immunogenicity research, the immune response data of people aged 3- 17 and 18 years or older after three doses of COVID-19 vaccine were better than two doses.

The overall research results show that the inactivated China COVID-19 vaccine of Sinopharm Group has good safety and tolerance after being inoculated with 3 doses in people over 3 years old, and can induce strong antibody reaction.

In addition, China Bio, a subsidiary of Sinopharm Group, conducted intensive research on 9,300 people in the United Arab Emirates. The interval between the second and third injections is about 6 months. The safety data is also in line with expectations, and there is no serious adverse events. Immunogenic results are being monitored.

_ Is it effective for mutant strains and why?

Laboratory data and some real-world studies show that China biological inactivated vaccine is still effective against Delta and other mutants, and China Biological has been closely observing the mutation in COVID-19. The research and development of inactivated vaccine for South African mutant and Delta mutant is in progress, and the information has been submitted to the regulatory authorities in a rolling way, and the progress will be announced to the public in time after approval.

The inactivated COVID-19 vaccine developed by biotechnology in China is produced with whole virus through a safe inactivation process, which keeps the diversity of virus antigens. Inoculation of inactivated vaccine can simulate the process of COVID-19 infection in vivo and stimulate the body to produce broad-spectrum antibodies. Therefore, COVID-19 inactivated vaccine has the advantages of broad antigen spectrum and resistance to mutant strains.

_ Who should give priority to booster injections?

It should be some special people, such as the elderly over 60, who are most closely related to social and economic activities, including catering, aviation, express delivery practitioners and so on.

_ Can I choose reinforcing needles with different technical routes?

The technical guideline for vaccination in COVID-19 issued by China suggested that the same vaccine product should be used to complete vaccination.

_ Is it the "third needle" or the mutated "second needle" that is first strengthened?

From the point of view of ordinary people, the booster should be chosen first in the future.